<DOC>
	<DOCNO>NCT00477126</DOCNO>
	<brief_summary>To establish bioequivalence ritonavir generic capsule , Norvir® reference drug .</brief_summary>
	<brief_title>Bioequivalence Study Generic GPO Ritonavir Versus Norvir®</brief_title>
	<detailed_description>This study perform evaluate new generic GPO ritonavir product bio-equivalent Norvir compare short-term tolerability safety profile .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Written inform consent Healthy male female 1845 year old Documented negative test HIV1 infection &lt; 1 wk prior start study risk HIV exposure last 6 month For female subject : document negative pregnancy test &lt; 3 wk prior start study , breastfeed BMI 1825 Normal physical examination Normal CBC , BUN , Cr , AST , ALT , Total bilirubin , evidence active chronic HBV HCV Infection History sensitivity/idiosyncrasy drug chemically related compound excipients , may employ study . Relevant history current condition might interfere drug absorption , distribution , metabolism excretion . Inability understand nature extent study procedure require . Participation drug study within 60 day prior first dose . Febrile illness within 3 day first dose . Use concomitant medication Smoke cigarettes 10 cigarette day . Drink alcohol 2 unit day Discontinue smoke alcohol least 1 month enrollment . Take medication regularly Involvement drug addiction Heart disease , hypertension , liver disease , kidney disease , GI disease , allergic disease disease may interfere PK study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>ritonavir generic capsule</keyword>
	<keyword>Norvir®</keyword>
	<keyword>Thailand</keyword>
	<keyword>Determine bioequivalence Norvir GPO ritonavir</keyword>
</DOC>